Compara mètodes
Revisa els mètodes seleccionats l'un al costat de l'altre; les files que difereixen es ressalten.
| Escala de Gravetat del Suïcidi de Columbia (C-SSRS)× | Impressió Global del Pacient sobre el Canvi (PGIC)× | |
|---|---|---|
| Camp | Psicologia clínica | Psicologia clínica |
| Família | Process / pipeline | Process / pipeline |
| Any d'origen≠ | 2008 | 1976 |
| Autor original≠ | Kelly Posner | William Guy |
| Tipus≠ | Clinician-administered interview scale | Self-report single-item rating |
| Font seminal≠ | Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., & Shen, S. (2011). The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry, 168(12), 1266–1277. DOI ↗ | Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, US Department of Health, Education, and Welfare. link ↗ |
| Àlies | C-SSRS, Columbia Suicide Severity Rating Scale | PGIC, Patient Global Impression of Change Scale |
| Relacionats | 4 | 4 |
| Resum≠ | The Columbia-Suicide Severity Rating Scale is a brief clinician-administered assessment of suicide risk developed by Kelly Posner and colleagues at Columbia University to address limitations in prior screening tools. First published in the American Journal of Psychiatry in 2011, the C-SSRS has become the FDA-endorsed standard for monitoring suicidal ideation and behavior in antidepressant, anticonvulsant, and neuropsychiatric medication trials. The scale assesses both suicidal ideation (frequency and intensity) and suicidal behavior (attempts, preparatory acts) over defined time windows, providing structured risk stratification. | The Patient Global Impression of Change is a single-item, seven-point rating scale asking patients to report their overall impression of change since treatment initiation. Originally published by William Guy in the ECDEU Assessment Manual in 1976, the PGIC has become a standard co-primary endpoint in clinical trials assessing treatment efficacy. The scale is endorsed by the FDA as a patient-reported outcome measure for demonstrating clinical benefit. Despite its simplicity, the PGIC captures patients' holistic perception of improvement—integrating symptom reduction, functional recovery, and subjective well-being. |
| ScholarGateConjunt de dades ↗ |
|
|